Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology.
The British Association for Psychopharmacology (BAP) coordinated a meeting of experts to review the evidence on the drug treatment for dementia. The level of evidence (types) was rated using a standard system: Types 1a and 1b (evidence from meta-analysis of randomised controlled trials or at least o...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2006
|
| _version_ | 1826279053727891456 |
|---|---|
| author | Burns, A O'Brien, J Auriacombe, S Ballard, C Broich, K Bullock, R Feldman, H Ford, G Knapp, M McCaddon, A Iliffe, S Jacova, C Jones, R Lennon, S McKeith, I Orgogozo, J Purandare, N Richardson, M Ritchie, C Thomas, A Warner, J Wilcock, G Wilkinson, D |
| author_facet | Burns, A O'Brien, J Auriacombe, S Ballard, C Broich, K Bullock, R Feldman, H Ford, G Knapp, M McCaddon, A Iliffe, S Jacova, C Jones, R Lennon, S McKeith, I Orgogozo, J Purandare, N Richardson, M Ritchie, C Thomas, A Warner, J Wilcock, G Wilkinson, D |
| author_sort | Burns, A |
| collection | OXFORD |
| description | The British Association for Psychopharmacology (BAP) coordinated a meeting of experts to review the evidence on the drug treatment for dementia. The level of evidence (types) was rated using a standard system: Types 1a and 1b (evidence from meta-analysis of randomised controlled trials or at least one controlled trial respectively); types 2a and 2b (one well-designed study or one other type of quasi experimental study respectively); type 3 (non-experimental descriptive studies); and type 4 (expert opinion). There is type 1a evidence for cholinesterase inhibitors (donepezil, rivastigmine and galantamine) for mild to moderate Alzheimer's disease; memantine for moderate to severe Alzheimer's disease; and for the use of bright light therapy and aromatherapy. There is type 1a evidence of no effect of anti inflammatory drugs or statins. There is conflicting evidence regarding oestrogens, with type 2a evidence of a protective effect of oestrogens but 1b evidence of a harmful effect. Type 1a evidence for any effect of B12 and folate will be forthcoming when current trials report. There is type 1b evidence for gingko biloba in producing a modest benefit of cognitive function; cholinesterase inhibitors for the treatment of people with Lewy body disease (particularly neuropsychiatric symptoms); cholinesterase inhibitors and memantine in treatment cognitive impairment associated with vascular dementia; and the effect of metal collating agents (although these should not be prescribed until more data on safety and efficacy are available). There is type 1b evidence to show that neither cholinesterase inhibitors nor vitamin E reduce the risk of developing Alzheimer's disease in people with mild cognitive impairment; and there is no evidence that there is any intervention that can prevent the onset of dementia. There is type 1b evidence for the beneficial effects of adding memantine to cholinesterase inhibitors, and type 2b evidence of positive switching outcomes from one cholinesterase inhibitor to another. There is type 2a evidence for a positive effect of reminiscence therapy, and type 2a evidence that cognitive training does not work. There is type 3 evidence to support the use of psychological interventions in dementia. There is type 2 evidence that a clinical diagnosis of dementia can be made accurately and that brain imaging increases that accuracy. Although the consensus statement dealt largely with medication, the role of dementia care in secondary services (geriatric medicine and old age psychiatry) and primary care, along with health economics, was discussed. There is ample evidence that there are effective treatments for people with dementia, and Alzheimer's disease in particular. Patients, their carers, and clinicians deserve to be optimistic in a field which often attracts therapeutic nihilism. |
| first_indexed | 2024-03-06T23:53:05Z |
| format | Journal article |
| id | oxford-uuid:7348de19-ca11-447c-a8b3-57abafda2fdf |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T23:53:05Z |
| publishDate | 2006 |
| record_format | dspace |
| spelling | oxford-uuid:7348de19-ca11-447c-a8b3-57abafda2fdf2022-03-26T19:55:30ZClinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:7348de19-ca11-447c-a8b3-57abafda2fdfEnglishSymplectic Elements at Oxford2006Burns, AO'Brien, JAuriacombe, SBallard, CBroich, KBullock, RFeldman, HFord, GKnapp, MMcCaddon, AIliffe, SJacova, CJones, RLennon, SMcKeith, IOrgogozo, JPurandare, NRichardson, MRitchie, CThomas, AWarner, JWilcock, GWilkinson, DThe British Association for Psychopharmacology (BAP) coordinated a meeting of experts to review the evidence on the drug treatment for dementia. The level of evidence (types) was rated using a standard system: Types 1a and 1b (evidence from meta-analysis of randomised controlled trials or at least one controlled trial respectively); types 2a and 2b (one well-designed study or one other type of quasi experimental study respectively); type 3 (non-experimental descriptive studies); and type 4 (expert opinion). There is type 1a evidence for cholinesterase inhibitors (donepezil, rivastigmine and galantamine) for mild to moderate Alzheimer's disease; memantine for moderate to severe Alzheimer's disease; and for the use of bright light therapy and aromatherapy. There is type 1a evidence of no effect of anti inflammatory drugs or statins. There is conflicting evidence regarding oestrogens, with type 2a evidence of a protective effect of oestrogens but 1b evidence of a harmful effect. Type 1a evidence for any effect of B12 and folate will be forthcoming when current trials report. There is type 1b evidence for gingko biloba in producing a modest benefit of cognitive function; cholinesterase inhibitors for the treatment of people with Lewy body disease (particularly neuropsychiatric symptoms); cholinesterase inhibitors and memantine in treatment cognitive impairment associated with vascular dementia; and the effect of metal collating agents (although these should not be prescribed until more data on safety and efficacy are available). There is type 1b evidence to show that neither cholinesterase inhibitors nor vitamin E reduce the risk of developing Alzheimer's disease in people with mild cognitive impairment; and there is no evidence that there is any intervention that can prevent the onset of dementia. There is type 1b evidence for the beneficial effects of adding memantine to cholinesterase inhibitors, and type 2b evidence of positive switching outcomes from one cholinesterase inhibitor to another. There is type 2a evidence for a positive effect of reminiscence therapy, and type 2a evidence that cognitive training does not work. There is type 3 evidence to support the use of psychological interventions in dementia. There is type 2 evidence that a clinical diagnosis of dementia can be made accurately and that brain imaging increases that accuracy. Although the consensus statement dealt largely with medication, the role of dementia care in secondary services (geriatric medicine and old age psychiatry) and primary care, along with health economics, was discussed. There is ample evidence that there are effective treatments for people with dementia, and Alzheimer's disease in particular. Patients, their carers, and clinicians deserve to be optimistic in a field which often attracts therapeutic nihilism. |
| spellingShingle | Burns, A O'Brien, J Auriacombe, S Ballard, C Broich, K Bullock, R Feldman, H Ford, G Knapp, M McCaddon, A Iliffe, S Jacova, C Jones, R Lennon, S McKeith, I Orgogozo, J Purandare, N Richardson, M Ritchie, C Thomas, A Warner, J Wilcock, G Wilkinson, D Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology. |
| title | Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology. |
| title_full | Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology. |
| title_fullStr | Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology. |
| title_full_unstemmed | Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology. |
| title_short | Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology. |
| title_sort | clinical practice with anti dementia drugs a consensus statement from british association for psychopharmacology |
| work_keys_str_mv | AT burnsa clinicalpracticewithantidementiadrugsaconsensusstatementfrombritishassociationforpsychopharmacology AT obrienj clinicalpracticewithantidementiadrugsaconsensusstatementfrombritishassociationforpsychopharmacology AT auriacombes clinicalpracticewithantidementiadrugsaconsensusstatementfrombritishassociationforpsychopharmacology AT ballardc clinicalpracticewithantidementiadrugsaconsensusstatementfrombritishassociationforpsychopharmacology AT broichk clinicalpracticewithantidementiadrugsaconsensusstatementfrombritishassociationforpsychopharmacology AT bullockr clinicalpracticewithantidementiadrugsaconsensusstatementfrombritishassociationforpsychopharmacology AT feldmanh clinicalpracticewithantidementiadrugsaconsensusstatementfrombritishassociationforpsychopharmacology AT fordg clinicalpracticewithantidementiadrugsaconsensusstatementfrombritishassociationforpsychopharmacology AT knappm clinicalpracticewithantidementiadrugsaconsensusstatementfrombritishassociationforpsychopharmacology AT mccaddona clinicalpracticewithantidementiadrugsaconsensusstatementfrombritishassociationforpsychopharmacology AT iliffes clinicalpracticewithantidementiadrugsaconsensusstatementfrombritishassociationforpsychopharmacology AT jacovac clinicalpracticewithantidementiadrugsaconsensusstatementfrombritishassociationforpsychopharmacology AT jonesr clinicalpracticewithantidementiadrugsaconsensusstatementfrombritishassociationforpsychopharmacology AT lennons clinicalpracticewithantidementiadrugsaconsensusstatementfrombritishassociationforpsychopharmacology AT mckeithi clinicalpracticewithantidementiadrugsaconsensusstatementfrombritishassociationforpsychopharmacology AT orgogozoj clinicalpracticewithantidementiadrugsaconsensusstatementfrombritishassociationforpsychopharmacology AT purandaren clinicalpracticewithantidementiadrugsaconsensusstatementfrombritishassociationforpsychopharmacology AT richardsonm clinicalpracticewithantidementiadrugsaconsensusstatementfrombritishassociationforpsychopharmacology AT ritchiec clinicalpracticewithantidementiadrugsaconsensusstatementfrombritishassociationforpsychopharmacology AT thomasa clinicalpracticewithantidementiadrugsaconsensusstatementfrombritishassociationforpsychopharmacology AT warnerj clinicalpracticewithantidementiadrugsaconsensusstatementfrombritishassociationforpsychopharmacology AT wilcockg clinicalpracticewithantidementiadrugsaconsensusstatementfrombritishassociationforpsychopharmacology AT wilkinsond clinicalpracticewithantidementiadrugsaconsensusstatementfrombritishassociationforpsychopharmacology |